Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
List view / Grid view
Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
Researchers have shown that natural killer cell immunotherapy effectively treated mice harbouring human melanoma tumours.
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
Dr Jo Brewer outlines research into allogeneic products by gene editing stem cells, which has the potential to build a broad family of multiple immune cell types, including T-cell therapies.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
Researchers have found that the gene mesothelin can be targeted by new antibody-drug conjugates to treat acute myeloid leukaemia in children.
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
Imaging Mass Cytometry™ of malignant tissue architecture: rare single cells to structured multi-cellular communities
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.